

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-143) DEPEMOKIMAB
 PRONUNCIATION dep" e mok' i mab
 THERAPEUTIC CLAIM Treatment of asthma

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human interleukin 5) (human-Mus musculus monoclonal GSK3511294 γ 1-chain), disulfide with human-Mus musculus monoclonal GSK3511294 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G1-kappa, anti-[Homo sapiens IL5 (interleukin 5, IL-5)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-449) [VH humanized (Homo sapiens IGHV2-70*19 (75.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -Homo sapiens IGHG1*03 G1m3, nG1m1, G1v21 CH2 Y15.1, T16, E18 (CH1 R120 (216) (120- 217), hinge 1-15 (218-232), CH2 M15.1>Y (254), S16>T (256), T18>E (258) (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-220')-disulfide with kappa light chain humanized (1'- 220') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.1%) -IGKJ2*02 (90.9%)) CDR-IMGT [12.3.9] (27-38.56-58.95-103) (1'-113') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO)-K1 cell line lacking the glutamine synthetase (GS) gene, glycoform alfa (Source: WHO pINN list 123)

STRUCTURAL FORMULA

Heavy chain

QVTLRESGPA	LVKPTQTLTL	TCTVSGFSLT	GSSVHWVRQP	PGKGLEWLGV	50
IWASGGTDYN	SALMSRLSIS	KDTSRNQVVL	TMTNMDPVDT	ATYYCARDPP	100
SGLLRLDYWG	RGTLVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDRVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250
DTLYITREPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSREEM	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	450

Light chain

DIVMTQSPDS	LAVSLGERAT	INCKSSQSL	NSGNQKNYLA	WYQQKPGQPP	50'
KLLIYGASTR	ESGVPDRFSG	SGSGTDFTLT	ISSLAEDVA	VYQCQNVHSF	100'
PFTFGGGTKL	EIKRTVAAPS	VFIFPPSDEQ	LKSGTASVVC	LLNNFYPREA	150'
KVQWKVDNAL	QSGNSQESVT	EQDSDKSTYS	LSSTLTLSKA	DYEKHKVYAC	200'
EVTHQGLSSP	VTKSFNRGEC				220'

Disulfide bridges

22-95	22''-95''	23'-94'	23'''-94'''	140'-200'	140'''-200'''	146-202	146''-202''
222-220'	222''-220'''	228-228''	231-231'''	263-323	263'''-323'''	369-427	369''-427''

Glycosylation sites (N)

None

MOLECULAR FORMULA	C ₆₄₇₄ H ₁₀₁₀₈ N ₁₇₃₄ O ₂₀₂₅ S ₄₄
MOLECULAR WEIGHT	148.7 kDa
TRADEMARK	None as yet
SPONSOR	GlaxoSmithKline
CODE DESIGNATIONS	GSK3511294, AQ82742999
<u>CAS</u> REGISTRY NUMBER	2243274-14-6
UNII	D16EQP0KKH
WHO NUMBER	11449

gbk